Karyopharm Therapeutics | KPTI - Cost Of Sales


Karyopharm Therapeutics reported $37.43M in Cost of Sales for its fiscal quarter ending in September of 2024.





Cost Of Sales Change Date
AbbVie USD 4.55B 757M Dec/2025
Abbott USD 4.92B 535M Dec/2025
Amgen USD 1.79B 128M Dec/2025
AstraZeneca USD 3.27B 471M Dec/2025
BioCryst Pharmaceuticals USD 12.27M 9.04M Dec/2024
Bristol-Myers Squibb USD 4.92B 657M Dec/2025
Eli Lilly USD 3.37B 363.7M Dec/2025
GlaxoSmithKline GBP 2.61B 377M Dec/2025
Incyte USD 121.18M 22.18M Dec/2025
J&J USD 7.97B 689M Dec/2025
Karyopharm Therapeutics USD 37.43M 2.41M Sep/2024
MacroGenics USD 44.3M 5.4M Sep/2025
Merck USD 3.32B 531M Dec/2025
Nektar Therapeutics USD 4.43M 5.3M Sep/2024
Novartis USD 3.54B 217M Sep/2025
Novartis USD 3.54B 216M Sep/2025
Pfizer USD 6.29B 2.12B Dec/2025
Regeneron Pharmaceuticals USD 584.6M 63M Dec/2025
Roche Holding CHF 8.48B 4.61B Dec/2025
Sangamo BioSciences 2.42M 1.11M Jun/2024
Takeda JPY 401.15B 184.07B Dec/2025
TG Therapeutics USD 38.14M 10.05M Dec/2025
Ultragenyx Pharmaceutical USD 29M 1.01M Dec/2025
Xencor USD 61.66M 50.95M Jun/2025